Claim 20% Off Global Market Reports With Code ONLINE20 – Insights on Tariff Effects, Global Trade, and Industry Disruptors

How Is The Alzheimer’s Drugs Market Expected To Grow In Terms Of Size?

The market for Alzheimer’s drugs has seen significant growth recently. The market will expand from $9.33 billion in 2024 to reach $10.09 billion in 2025, representing a compound annual growth rate (CAGR) of 8.1%. The remarkable growth observed in the previous period can be linked to an increase in Alzheimer’s disease incidences, research and development investment, enhanced comprehension of disease pathways, worldwide health campaigns, and increased public awareness and education.

The market size for Alzheimer’s drugs is predicted to witness robust growth in the upcoming years, escalating to an estimated $14.16 billion by 2029, with a Compound Annual Growth Rate (CAGR) of 8.8%. The projected growth during this period can be credited to advanced precision medicine tactics, concentration on disease alterations, substantiation and identification of biomarkers, patient-focused drug development, and emphasis on non-medical interventions. The major trends expected during this period encompass various therapeutic strategies, digital health innovations, regenerative medicine, breakthroughs in diagnostic technologies, the application of artificial intelligence (AI) in drug discovery, and strategic partnerships and collaborations.

Get A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=9040&type=smp

What External And Internal Drivers Are Influencing The Alzheimer’s Drugs Market?

The growth of the Alzheimer’s drugs market is anticipated to be propelled by the escalating occurrence of Alzheimer’s disease. This neurological disorder gradually worsens, leading to brain shrinkage and cell death. Alzheimer’s medications are employed to address memory loss, cognitive issues, and daily life challenges. These medications can improve life quality and assist in maintaining independence. For example, the Alzheimer’s Association, a US-based nonprofit engaged in Alzheimer’s care, support, and research, reported in May 2024 that the count of Americans aged 65 and above diagnosed with Alzheimer’s dementia increased from 6.5 million in 2022 to an estimated 6.9 million in 2024. Hence, the surging prevalence of Alzheimer’s disease is fueling the expansion of the Alzheimer’s drugs market.

Which Segment Accounts For The Largest Share In The Alzheimer’s Drugs Market?

The alzheimer’s drugs market covered in this report is segmented –

1) By Drugs: Donepezil, Rivastigmine, Galantamine, Memantine

2) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy

3) By Application: Early To Moderate Stages, Moderate To Severe Stages

Subsegments:

1) By Donepezil: Oral Tablets, Oral Solution

2) By Rivastigmine: Oral Capsules, Oral Solution, Transdermal Patches

3) By Galantamine: Oral Tablets, Oral Solution, Extended-Release Capsules

4) By Memantine: Oral Tablets, Oral Solution, Extended-Release Capsules

Which Long-Term Trends Will Play A Crucial Role In The Alzheimer’s Drugs Market?

Key players in the Alzheimer’s drugs market are pioneering novel treatments such as amyloid plaque-targeting therapy to enhance treatment alternatives and better patient results. This therapeutic strategy for Alzheimer’s aims to lessen or inhibit the build-up of amyloid-beta plaques in the brain. For example, in June 2024, Eli Lilly and Company, a pharmaceutical corporation based in the US, obtained approval for Kisunla (donanemab-azbt) from the US Food and Drug Administration(FDA), a US federal organization committed to public health preservation. Kisunla (donanemab-azbt) is the premier and sole amyloid plaque-targeting therapy for early symptomatic Alzheimer’s disease. Its function is to assist the body in eliminating excessive amyloid plaques from the brain, these plaques are linked to cognitive deterioration in Alzheimer’s sufferers. Kisunla is given as an intravenous infusion on a monthly basis. The beginning dosing plan encompasses 700 mg for the primary three doses, later followed by 1400 mg. Kisunla is particularly designated for adults manifesting mild cognitive diminution (MCI) and mild dementia phases of Alzheimer’s disease, as long as they have validated amyloid pathology.

Which Players Are Shaping The Competitive Landscape Of The Alzheimer’s Drugs Market?

Major companies operating in the alzheimer’s drugs market include AbbVie Inc., Daiichi Sankyo Company Limited, F Hoffmann-La Roche AG, Merck & Co Inc., Novartis AG, Biogen Inc., AstraZeneca PLC, Eisai Co Ltd., Eli Lilly and Company, H Lundbeck A/S, Pfizer Inc., Allergan PLC., Johnson & Johnson, Lupin Pharmaceuticals Inc., Actiza Pharmaceutical Private Limited, Neurotrope Inc., AC Immune SA, Adamas Pharmaceuticals Inc, Alzheon Inc., Anavex Life Sciences Corp, Axsome Therapeutics Inc., Cassava Sciences Inc., Cognition Therapeutics Inc., Cortexyme Inc., Denali Therapeutics Inc, EIP Pharma Inc., Enlivex Therapeutics Ltd., FORUM Pharmaceuticals Inc., Genentech Inc., Green Valley Pharmaceuticals LLC, Intra-Cellular Therapies Inc., Karuna Therapeutics Inc., Neurim Pharmaceuticals Ltd

Access The Complete Report Here:

https://www.thebusinessresearchcompany.com/report/alzheimers-drugs-global-market-report

What Regional Factors Are Accelerating Growth In The Alzheimer’s Drugs Market?

North Americawas the largest region in the Alzheimer’s drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the Alzheimer’s drugs market during the forecast period. The regions covered in the Alzheimer’s drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Customize Your Report Here:

https://www.thebusinessresearchcompany.com/customise?id=9040&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model